BioDelivery Sciences International (FRA:BD5) Accounts Payable & Accrued Expense : €63.4 Mil (As of Dec. 2021)

View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Accounts Payable & Accrued Expense?

BioDelivery Sciences International's quarterly accounts payable & accrued expense increased from Jun. 2021 (€42.9 Mil) to Sep. 2021 (€57.6 Mil) and increased from Sep. 2021 (€57.6 Mil) to Dec. 2021 (€63.4 Mil).

BioDelivery Sciences International's annual accounts payable & accrued expense declined from Dec. 2019 (€43.6 Mil) to Dec. 2020 (€39.1 Mil) but then increased from Dec. 2020 (€39.1 Mil) to Dec. 2021 (€63.4 Mil).

BioDelivery Sciences International Accounts Payable & Accrued Expense Historical Data

The historical data trend for BioDelivery Sciences International's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Accounts Payable & Accrued Expense Chart

BioDelivery Sciences International Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

19.16

15.58

43.60

39.05

63.42

BioDelivery Sciences International Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															39.05	41.82	42.86	57.59	63.42

BioDelivery Sciences International Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

BioDelivery Sciences International (FRA:BD5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612

Website

http://www.bdsi.com

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines